8-K filing — Profound Medical Corp. (PROF)
Filed: 2026-08-17 AccNo: 0001171843-26-005580 Size: 225 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same period last year. The
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:20 PM
- Checked
- Aug 6, 2026, 8:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
Read original at benzinga